Sitemap

September 08, 2019 Articles

Filter by Available Specialty
  1. Ipilimumab-nivolumab combination safe for historically unstudied patients with lung cancer
  2. Novel KRAS inhibitor induces disease control in 96% of treated patients with non-small cell lung cancer
  3. Read OSN's Sept. 10 publication exclusives online
  4. Researchers identify mutations associated with treatment sensitivity, resistance in NSCLC
  5. Survey shows low uptake of surgical antimicrobial prophylaxis guidelines
  6. Top 10 recent diet and nutrition news reports
  7. Top intervention news of August: TAVR low-risk indications, FDA paclitaxel advisory and more
  8. Trigger finger release in OR at one center associated with higher cost vs in the procedure room